Ridgeback Biotherapeutics

Ridgeback Biotherapeutics is a private, clinical-stage biotech company specializing in antiviral therapeutics for high-need, emerging infectious diseases. Founded and led by healthcare investors Wendy and Wayne Holman, the company has successfully advanced two late-stage assets: the FDA-approved Ebola treatment EBANGA™ and the oral antiviral Lagevrio (molnupiravir) for COVID-19. Ridgeback's strategy centers on identifying and accelerating promising science for pathogens that are often overlooked by larger pharmaceutical players, positioning itself at the intersection of public health response and drug development. The company operates with a lean, virtual model, leveraging partnerships for development and commercialization.

Strategic model of in-licensing and rapidly advancing existing small molecule antiviral candidates, often from academic or government sources, through clinical development and partnerships.

Ridgeback competes with large pharmaceutical companies (e.g., Pfizer, Gilead, Roche) and other biotechs in the antiviral space. Its differentiation lies in its focused, agile model targeting niche or overlooked infectious diseases early. For COVID-19, it faces direct competition from Paxlovid and other therapies. In Ebola, it competes with other monoclonal antibodies like Regeneron's Inmazeb.